TuHURA Biosciences, Inc./NV
HURANext catalyst
IFx-Hu2.0
Advanced Or Metastatic Merkel Cell Carcinoma
Get an email about HURA's next catalysts
Track TuHURA Biosciences, Inc./NV (HURA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
IFx-Hu2.0 Phase 3 Est. Readout
Estimated primary completion for IFx-Hu2.0 trial (NCT06947928) in Advanced Or Metastatic Merkel Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IFx-Hu2.0 | Phase 3 | Advanced Or Metastatic Merkel Cell Carcinoma | - | - |
Frequently asked questions
What is in TuHURA Biosciences, Inc./NV's drug pipeline?β
CatalystAlert tracks 1 drug candidate in TuHURA Biosciences, Inc./NV's (HURA) pipeline across Phase 3. Its lead program is IFx-Hu2.0 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TuHURA Biosciences, Inc./NV's next FDA catalyst?β
TuHURA Biosciences, Inc./NV's (HURA) next tracked catalyst is a Phase 3 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HURA biotech catalysts?β
Add HURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TuHURA Biosciences, Inc./NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
